Abstract
The market entry of biosimilars has represented a cost-reduction opportunity for healthcare systems across Europe. To seize this opportunity in the long term, systems’ rely on ensuring a sustainable competitive environment for all the market players. However, European experiences show that the level of competition generated by biosimilars varies by country, care setting and molecule. Biosimilars contribution to attaining price reductions and increased treatments’ access varies consequently. We aim to capture market dynamics for tumor necrosis factor (TNF)-alpha inhibitors in Southern Europe. The rationale behind this study is the need to gain an in- depth understanding on the impact of the competition generated by the availability of biosimilars in diverse market environments.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
